newwin
Luciann Nguyen
Settings
← Accounts
biotech

Ranok Therapeutics (Hangzhou) Co., Ltd.

70
Account opportunity
Not established
Relationship
1
Active signals
1
Trials as sponsor

Why this account matters

Ranok Therapeutics (Hangzhou) Co., Ltd.

New trial — A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation

New trialNCT06667544
70/100
Opportunity
Commercial fit18/25
Clinical timing20/20
Biomarker need15/20
Relationship2/10
Signal strength9/10
Account value5/10
Urgency1/5

New phase 1_2 trial NCT06667544 posted by Ranok Therapeutics (Hangzhou) Co., Ltd.: "A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation". New trial on a phase 1_2 recruiting study is a moment when external vendors are commonly selected or expanded (spec §70).

Why nowClinicalTrials.gov record updated 313 days ago.

ConfidenceHigh · 95%clinical development · translational medicine · clinical operations
Draft outreachReview

NextMap clinical development and translational medicine stakeholders on the sponsor, confirm no colleague is mid-conversation, then draft evidence-based outreach.

Trials

TrialPhaseTesting language
NCT06667544
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
phase 1 2
mol. elig.ctDNA